A Phase 2, Randomized, Double-blind Study Comparing Trem

Project: Research project

Description

A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second-or Third-line Treatment of Subjects with Unresectable or Peritoneal Malignant Mesothelioma
StatusFinished
Effective start/end date6/1/13 → 6/30/18

Funding

  • MedImmune, LLC
View all
View less

Fingerprint

Double-Blind Method
Placebos
Therapeutics
tremelimumab
Malignant Mesothelioma